Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
12 Julho 2023 - 10:00AM
Business Wire
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the
“Company”) today announced the Company will host a virtual webcast
with Prof. Dr. Günter H�glinger, Director of the Department of
Neurology at LMU Hospital, Ludwig-Maximilians-University (LMU)
Munich, Germany, to discuss the treatment landscape for people
living with progressive supranuclear palsy (PSP) and the Company’s
clinical development plans for AMX0035 in PSP on July 26, 2023 at
1:30pm ET.
A live webcast of the presentation can be accessed under “Events
and Presentations” in the Investor section of the Company’s
website, https://investors.amylyx.com/news-events/events, and will
be available for replay for 90 days following the event.
Prof. Dr. H�glinger conducts research in the field of
neurodegenerative Parkinson syndromes with the goal of
understanding the molecular mechanisms leading to the development
and progression of neuronal dysfunction and death and of using
these findings for diagnostic and therapeutic purposes. His
particular focus is the interface between preclinical and clinical
research. Prof. Dr. H�glinger studied medicine and physics at the
universities of Regensburg and Würzburg and earned his PhD in
medicine, summa cum laude, in 2000.
Supported by a grant from the German Research Foundation, DFG,
he worked as a postdoctoral researcher at the Hôpital de la
Salpêtrière in Paris. Since 2004, he has directed the experimental
neurology research group at Philipps University Marburg and went on
to work as the Vice Director of the Department of Neurology. Since
2011, he has held the Chair of the Department of Translational
Neurodegeneration at the German Center for Neurodegenerative
Diseases, DZNE. Beginning in 2019, he has also served as the
President of the German Parkinson Association and Director of the
Department of Neurology at Hannover Medical School. For many years,
Prof. Dr. H�glinger has been conducting translational research into
tauopathies and was actively involved in many international
clinical trials in PSP.
About RELYVRIO®/ ALBRIOZA™ / ALBRIOZA® / AMX0035
RELYVRIO® (also known as AMX0035), an oral, fixed-dose
combination of sodium phenylbutyrate and taurursodiol (known as
ursodoxicoltaurine outside of the U.S.), is approved to treat
amyotrophic lateral sclerosis (ALS) in adults in the U.S. and
approved with conditions as ALBRIOZA™ for the treatment of ALS in
Canada. The Committee for Medicinal Products for Human Use (CHMP)
of the European Medicines Agency (EMA) is re-examining its initial
opinion on the current application for conditional marketing
authorisation of AMX0035, under the trade name ALBRIOZA®, for the
treatment of ALS in the European Union. AMX0035 is being explored
for the potential treatment of other neurodegenerative diseases.
The formulation of RELYVRIO, ALBRIOZA, and AMX0035 are
identical.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is committed to supporting and
creating more moments for the neurodegenerative disease community
through the discovery and development of innovative new treatments.
Amylyx is headquartered in Cambridge, Massachusetts and has
operations in Canada and EMEA. For more information, visit
amylyx.com and follow us on LinkedIn and Twitter. For investors,
please visit investors.amylyx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230712207804/en/
Media Amylyx Media Team +1 (857) 799-7274
amylyxmediateam@amylyx.com Investors Lindsey Allen Amylyx
Pharmaceuticals, Inc. +1 (857) 320-6244 Investors@amylyx.com
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024